Möchten Sie immer auf dem neuesten Stand bleiben?

COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE...

Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer

REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...

Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15...

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology

Belleville, Illinois, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Allsup, the nation’s leading provider of Social Security Disability Insurance (SSDI) representation services is championing Cervical Cancer...